GlaxoSmithKline Pharmaceuticals Limited — Q3 FY26 earnings call

Call held 9 Feb 2026

Management summary

GlaxoSmithKline Pharmaceuticals reported a milestone Q3 FY26, crossing INR 1,000 crores in consolidated revenue with ~10% growth. Profitability saw significant improvement, with EBITDA margin at 35.9% and PAT margin at 27.3%. The company resolved prior supply constraints and saw strong performance in vaccines and specialty, particularly with the expanded patient pool for Jemperli in oncology. Management reiterated its ambition for 12-14% annual growth to double the business to INR 8,000 crores in the next 4-5 years, driven by new product launches and sustained base business growth.

Highlights

  • Consolidated revenue crossed INR 1,000 crores for the first time, growing ~10% YoY.

  • EBITDA margin reached 35.9%, a 520 bps improvement, driven by gross margin improvement and cost control.

  • PAT margin improved by 290 bps to 27.3%, with EPS growth of 9%.

  • Supply constraints from the previous two quarters are resolved, with inventories building up for Q4 onwards.

  • The eligible patient pool for Jemperli in first-line endometrial cancer expanded from 800 to 6,000-7,000 patients following regulatory approval in December 2025.

Concerns

  • One-off labour cost impact of INR 11.8 crores was incurred during the quarter.

  • Lost sales of INR 25-30 crores due to CMO fire (not Augmentin site) impacted growth by ~3% in Q3.

Key financials

  1. Revenue (Standalone) ₹1,000 Cr +8.1%YoY
  2. Revenue (Consolidated) ₹1,000 Cr +10%YoY
  3. EBITDA Margin 35.9%
  4. EBITDA Growth — +26.7%YoY
  5. PAT Margin 27.3%
  6. EPS Growth — +9%YoY
  7. Cash Position ₹2,426 Cr

What they filed

Q1 FY27: revenue up 16.5%, net profit up 15.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,011 949 974 805 980 −3%1,041 +10%995 +2%938 +17%
EBITDA322 292 333 251 336 +4%371 +27%351 +5%296 +18%
Net profit252 230 263 205 257 +2%296 +29%278 +6%237 +16%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Liquidity Cash ₹2,426 Cr Company maintains a healthy cash position.
    EPS growth of 9% in the quarter and the cash position is quite healthy with INR2,426 crores.

Guidance & targets

Revenue

  • Annual Revenue Growth Revenue · next 5 years · High confidence 12-14%
    This organization has to grow in the range of 12% to 13% annually over the next five years so that we can double the business from where we were in '23-'24 to the point of becoming an INR8,000 crores business.

    — Bhushan Akshikar

  • Total Topline Revenue · next 4-5 years · High confidence INR 8,000 crores

    — Bhushan Akshikar

Product Performance

  • Shingrix Topline Product Performance · CY '25 · High confidence INR 70-75 crores
    In terms of values, it roughly translates around INR70 crores-INR75 crores. So that's where we are on a calendar basis.

    — Bhushan Akshikar

Profitability

  • EBITDA Margin Profitability · ongoing · High confidence 35.9%
    our endeavor will be to hold the margins and stay competitive and sustain these margins as opposed to spending any time to improve.

    — Bhushan Akshikar

  • PAT Margin Profitability · ongoing · High confidence 27.3%

    — Bhushan Akshikar

Product Portfolio

  • Freshness Index (New Products Contribution) Product Portfolio · coming financial year · High confidence 10-15%
    Today when you look at the coming financial year, that's a clearly stated intent that our oncology business, Shingrix which is about less than three years old, the RSV product that we will launch, Blenrep, all these products put together should be in the range of that 10%-15% mark.

    — Bhushan Akshikar

  • Freshness Index (New Products Contribution) Product Portfolio · over 5-7 year period · Medium confidence 20-25%
    I would probably safely hazard a number of around 20%-25% of the freshness index.

    — Bhushan Akshikar

Product Launches

  • New Brands (INR 500 crores+) Product Launches · next 7-8 years · Medium confidence 5-6
    Now can we have amongst maybe the next let's say we aspire to launch 5 new launches to 6 new launches over next 7 to 8 years? Do you fairly believe that with the paying potential in India, we can have a INR500 crores plus brands of these newer launches?

    — Monica Bhaskar

What to watch in Q4 FY26

Blenrep Launch & Initial Traction

Q2/Q3 FY27
Current Slated for launch in next financial year (Q2/Q3 latest)
Target Commercial launch and initial sales contribution from Blenrep for multiple myeloma.

Why it matters

Blenrep is a key new oncology asset expected to drive future growth, and its launch will be a significant milestone.

This year, we also have a couple of oncology assets lined up, including belantamab, which is Blenrep, which is for multiple myeloma. So that's another asset that we will get activated in the next financial year, this calendar year, but the next financial year.

Risks & concerns

  • Raw Material Price Volatility

    medium

    Base business (80% of portfolio) is dependent on API prices, which have been stable for 2 years, but changes could impact margins.

    Management acknowledged

  • Regulatory Approval Lag for New Products

    medium

    Despite global approvals, local regulatory approval can take 6-18 months, impacting simultaneous launches, though efforts are being made to fast-track.

    Management acknowledged

Q&A highlights

6 direct
Sustainability of EBITDA Margins and Impact of Duty-Free Cancer Meds Direct
our endeavor will be to hold the margins and stay competitive and sustain these margins as opposed to spending any time to improve. If that happens, it's an outcome. But I think our first priority will be to maintain the margins that we've now been able to sustain over the last three years.

Analyst questioned the sustainability of high margins, and management clarified their focus is on maintaining current levels rather than further expansion, and that GSK products were not impacted by recent duty-free cancer med announcements.

Asked by Mehul Savla

Impact of CMO Fire on Sales and Underlying Growth Direct
Just a small correction, it was not the Augmentin site at all. It was a site which was manufacturing products like Calpol, Cobadex CZS, and a few others. And those are the products that were impacted for almost three quarters, including Q3. So we did normalize largely by mid-November, December, but we still lost sales, there were supply constraints to the tune of roughly about INR25 crores, INR30 crores, shaving off almost 3% of our growth on our top line revenue.

Analyst inquired about supply disruptions, and management provided specific details on affected products, lost sales figures (INR 25-30 crores), and clarified that the underlying growth was higher (~11%) without these issues.

Asked by Ahmed

Shingrix Performance and Future Oncology Pipeline Direct
I can give you a rough estimate, but I think we are touching almost 9,000 to 10,000 patients every month. So in terms of volumes, it was almost 100,000 doses that we sold for the whole calendar year of last year, and we estimate that number will only go up as we close out our financial year. In terms of values, it roughly translates around INR70 crores-INR75 crores.

Analyst sought quantitative details on Shingrix and the oncology pipeline. Management provided specific patient and dose numbers for Shingrix and outlined key upcoming oncology and liver disease assets like Blenrep and Bepirovirsen.

Asked by Ahmed

Risk of Parent Company Launching Assets Directly in India Direct
I mean if you see the demonstrated evidence, we've had both Zejula and Jemperli being launched through the listed entity, so I don't see we've got data points to prove our intent and that will stay.

Analyst raised a common concern for Indian subsidiaries of MNCs. Management directly addressed this by citing recent examples of new product launches through the listed entity, reassuring investors of their intent.

Asked by Vamsi Hota

Profitability Trajectory with New Product Launches Direct
our objective will be to hold and sustain these margins which we've worked to deliver over the last three years. So that would be the objective rather than expanding gross margin any more or expanding the EBITDA.

Analyst questioned if profitability growth would mirror topline growth given heavier launch costs for innovative assets. Management clarified their focus is on sustaining current strong margins while investing for growth, implying profitability will grow in line with revenue.

Asked by Aejas

Regulatory Approval Timelines for New Products Partial
And the reason is simple because although you may have approvals in the Western world, it still takes anywhere between six months sometimes to 18 months to get approval from our local regulator. So I think the regulator also have stated their intent to fast-track and accelerate, but it's a function of therefore how things evolve in the coming months.

Analyst asked about simultaneous global and India launches. Management explained the regulatory lag (6-18 months) despite intent to fast-track, indicating that true simultaneity is still an evolving goal.

Asked by Viraj Mithani

Contribution of New Medicines to Topline in the Future Direct
Today when you look at the coming financial year, that's a clearly stated intent that our oncology business, Shingrix which is about less than three years old, the RSV product that we will launch, Blenrep, all these products put together should be in the range of that 10%-15% mark. ... I would probably safely hazard a number of around 20%-25% of the freshness index.

Analyst sought clarity on the future product mix. Management provided specific targets for the 'freshness index' (contribution from new products) for the coming FY (10-15%) and over the next 5-7 years (20-25%), highlighting the strategic shift.

Asked by Viraj Mithani

2 min read 6 chapters

Detailed narrative

Q3 FY26 Performance Overview

GlaxoSmithKline Pharmaceuticals reported a strong Q3 FY26, achieving a consolidated revenue of over INR 1,000 crores for the first time, marking approximately 10% year-on-year growth. Standalone revenue grew by 8.1%. The company's underlying growth, excluding INR 25-30 crores in lost sales due to a CMO fire, would have been around 11%. This performance was supported by the resolution of supply constraints that had impacted the previous two quarters, with inventories now building up for Q4 onwards.

Profitability Expansion

The quarter saw significant profitability improvements. EBITDA margin expanded by 520 basis points to 35.9%, driven by gross margin improvements and disciplined cost control, resulting in a 26.7% growth in EBITDA. PAT margin also improved by 290 basis points to 27.3%, contributing to a 9% growth in EPS. Management emphasized their focus on sustaining these improved margin levels, which have steadily increased from 24.3% two years ago.

Strategic Portfolio Shift and Growth Drivers

The company is actively transforming its portfolio, moving from established general medicines towards high-growth specialty and oncology segments. General medicines, including key brands like Augmentin, Ceftum, and T-Bact, returned to double-digit growth. The vaccine business continued its strong trajectory with 11% growth for the quarter, led by Boostrix, Varilrix, and Havrix. Specialty products like Nucala and Trelegy also contributed to growth, alongside the initial traction from the oncology portfolio.

Oncology and Specialty Expansion

Q3 FY26 marked the first full quarter for the oncology portfolio (Zejula and Jemperli). A significant development was the regulatory approval in December 2025 for Jemperli in first-line endometrial cancer (RUBY-1 trial), expanding the eligible patient pool from 800 to 6,000-7,000 patients. The company currently has approximately 250 patients on treatment with Zejula and Jemperli. Upcoming oncology assets include Blenrep for multiple myeloma, slated for launch in the next financial year (Q2/Q3 latest), and liver disease assets like Bepirovirsen and Efimosfermin, which have seen global trial readouts with Indian participation.

Long-Term Growth Ambition and Freshness Index

GlaxoSmithKline Pharmaceuticals aims to double its business to INR 8,000 crores over the next 4-5 years, targeting an annual revenue growth rate of 12-14%. This growth will be fueled by the sustained high single-digit growth of the base business and significant contributions from new launches in specialty and oncology. The company projects a 'freshness index' (contribution from products launched in the last 2-3 years) of 10-15% for the coming financial year, potentially rising to 20-25% over the next 5-7 years.

Digital Engagement and Field Force Strategy

The company continues to leverage its omnichannel strategy, combining face-to-face interactions with digital connections, achieving approximately 4 million HCP touch points in Q3. The field force of around 2,000 sales representatives in general medicines remains stable. Expansion of the field force is strategically focused on specialty areas like oncology and hematology, with a new hematology team planned for launch in the coming weeks/months to support new product introductions.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls